Opus Genetics, Inc. Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent
Opus Genetics, Inc. (IRD) reported Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent of $2.34 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2013-03-22.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent · last filed 2013-03-22
- Opus Genetics, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2011-12-31 was $0.00.
- Opus Genetics, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2011-09-30 was $0.00.
- Opus Genetics, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2011-06-30 was $3.70K.
- Opus Genetics, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2011-03-31 was -$1.36K.
- Opus Genetics, Inc. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for fiscal 2011 was $2.34K.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | $0.00 derived: sum of 2 quarters · filed 2013-03-22 | $3.70K derived: sum of 3 quarters · filed 2013-03-22 | $2.34K 10-K · filed 2013-03-22 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $3.70K derived: sum of 2 quarters · filed 2012-11-08 | $2.34K 10-Q · filed 2012-11-08 | |
| 2011-06-30 | $3.70K 10-Q · filed 2012-08-08 | $2.34K 10-Q · filed 2012-08-08 | ||
| 2011-03-31 | -$1.36K 10-Q · filed 2012-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |